Indonesia: COVID-19 vaccines market revenue growth 2028

In 2022, the annual revenue of the coronavirus (COVID-19) vaccine market in Indonesia declined by around 42.2 percent. The Statista Health Market Outlook estimated that the revenue of the market will further show negative growth until 2028.

Revenue growth of the COVID-19 vaccines market in Indonesia from 2022 to 2028

Characteristic	Revenue growth
-	-
-	-
-	-
-	-
-	-
-	-
-	-

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

More information

Supplementary notes

Data provided by Statista Market Insights are estimates.

This market covers vaccines against infectious diseases. They help to prevent diseases, usually through active immunization. Vaccines against infectious diseases transmitted by viruses (e.g., hepatitis A and B or COVID-19) and bacteria (e.g., typhoid fever or meningococcus) are included.

Market values represent revenues paid to primary vendors at manufacturer price level either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), enterprises (B2B) as well as governments (B2G).

Company examples: Pfizer, GlaxoSmithKline, Merck & Co, Sanofi, Moderna, AstraZeneca

A detailed methodology can be found in the Statista Market Outlook.

Citation formats